Additionally, elevated toxicity was observed while in the experimental group. Matu ration of information and even more analysis of subgroups, long term survivors, and also the result of other prognostic factors are ongoing. kinase inhibitor DNMT inhibitor TA 05. Treatment OF RECURRENT Higher GRADE GLIAL TUMORS WITH BEVACIZUMAB AND IRINOTECAN, PRELIMINARY Benefits Felix Bokstein and Deborah T. Blumenthal, Neuro Oncology Services, Tel Aviv Sourasky Healthcare Center, Tel Aviv, Israel Response costs to second line chemotherapy in recurrent high grade glial tumors are incredibly reduced, and new, powerful solutions are necessary. To eval uate response prices and tolerability of chemotherapy with bevacizumab and irinotecan in recurrent large grade glial tumors, we taken care of 12 individuals with recurrent gliomas with bevacizumab and irinotecan every 2 weeks. 10 sufferers had glioblastoma multiforme, 1 had grade III oligodendroglioma, and one had grade III oligoastrocytoma.
All sufferers had been previously handled with least 1 chemotherapy regimen. 4 individuals started therapy straight away right after surgical treatment. The treatment was initiated in eight sufferers following the previous therapy failed. Enzyme inducing antiepileptic medicines have been withdrawn, and sufferers were placed on nonenzyme inducing antiepileptic medicines in advance of starting up buy GSK2118436 remedy. Response was evaluated by gadolin ium enhanced MRI carried out every 4 cycles of treatment. Seventy 5 per cent of individuals responded to remedy, two showed comprehensive radiologi cal response, and 7 other folks showed an incredibly spectacular partial response using a over 50% lessen in volume of improving tumor. One among the individuals with CR finished the remedy after 16 cycles and was secure for 1 month. One particular patient that has a partial response soon after four cycles of treatment method had even more progression soon after an additional 8 cycles and gradually died of progressive disease.
As of Could 2006, all but one from the responding sufferers continued to obtain remedy just after four to twelve cycles of chemotherapy. Three sufferers designed rapid progression

of disease following 2 to 4 cycles of remedy, all of them with radiological signs of leptomenin geal or ependymal involvement. The remedy was well tolerated, 2 patients created transient diarrhea, one produced focal seizures, and 1 created transient weakness and fever. The adverse effects have been mild and did not go beyond grade II. These preliminary data show a promising higher response rate of recurrent large grade gliomas to chemotherapy with bevacizumab and irinotecan. This regimen is associated with minimal toxicity. TA 06. Finish RESPONSE OF A DIFFUSE INTRINSIC BRAINSTEM TUMOR AND VON HIPPEL LINDAU Sickness TO ANTINEOPLASTONS A10 AND AS2 one, A CASE REPORT S. R. Burzynski, R. A. Weaver, B. Szymkowski, T. J. Janicki, M.